510(k) Report

510(k) · Cleared

Cleared

Cerament Bone Void Filler

K201535510(k) TraditionalCleared Oct 16, 2020130-day reviewClass II21 CFR 888.3045

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bonesupport AB · MQV Filler, Bone Void, Calcium Compound

Cleared on Oct 16, 2020 as substantially equivalent to K073316 (Bonesupport AB, 2008) after a 130-day review. Its family tree reaches back 6 generations to 1996. 3 later devices descend from it.

Decided
Oct 16, 2020
Review
130 days
Class
Class II
Product code
MQV
Recalls
None
Predicates
1

Its longest line of descent runs back 6 generations to K960978 (1996). 14 ancestors in all, the oldest K910432 (1991). 3 later devices descend from it, 2 citing it directly.

  1. Root · 6 generations backK960978 Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc · 1996
  2. 5 generations backK980817 Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model…Interpore Intl. · 1998
  3. 4 generations backK030131 Ossatura BCP Bone Void FillerIsotis NV · 2003
  4. 3 generations backK033722 Apapore Bone Graft SubstituteApatech, Ltd. · 2004
  5. 2 generations backK051951 Cerament Bone Void FillerBonesupport AB · 2005
  6. 1 generation backK073316 Cerament Bone Void Filler, Model A0210Bonesupport AB · 2008
  7. This deviceK201535 Cerament Bone Void FillerBonesupport AB · 2020
  8. Descendant · cites it directly · 2 of its ownK212083 Tactoset Injectable Bone SubstituteAnika Therapeutics, Inc. · 2021
  9. Descendant · 2 generations on · 1 of its ownK223915 TactosetAnika Therapeutics, Inc. · 2023
  10. Descendant · cites it directly · 0 of its ownK231968 Tactoset® Injectable Bone SubstituteAnika Therapeutics, Inc. · 2023

Most influential descendants

Showing 3 of 3 · See all
  • K212083Tactoset Injectable Bone SubstituteAnika Therapeutics, Inc. · 2021 · cites it directly2descendants
  • K223915TactosetAnika Therapeutics, Inc. · 2023 · 2 generations on1descendant
  • K231968Tactoset® Injectable Bone SubstituteAnika Therapeutics, Inc. · 2023 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−6K960978Wright Plaster of Paris Pellets (Subject to Revision)Wrightmedicaltechnologyinc1996—
−5K980817Pro Osteon Implant 500R Resorbable Bone Graft Substitute Model Numbers 5RG05…Interpore Intl.1998—
−4K030131Ossatura BCP Bone Void FillerIsotis NV2003—
−3K033722Apapore Bone Graft SubstituteApatech, Ltd.2004—
−2K051951Cerament Bone Void FillerBonesupport AB2005—
−1K073316Cerament Bone Void Filler, Model A0210Bonesupport AB2008—
0 (this device)K201535Cerament Bone Void FillerBonesupport AB2020—
+1K212083Tactoset Injectable Bone SubstituteAnika Therapeutics, Inc.2021—
+2K223915TactosetAnika Therapeutics, Inc.2023—
+1K231968Tactoset® Injectable Bone SubstituteAnika Therapeutics, Inc.2023—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199110
199610
199710
200010
200110
200210
200320

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202110
202320
FIG. 1 — Lineage of K201535, 1996–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MQV? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MQV device

  1. #1 K232315 Catalyst Bone Void Fillerscore 25.2 · 25 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K073316Cerament Bone Void Filler, Model A0210
Summary page 5
…n be drilled and screws can be placed through it. Predicate Devices 510(k) Trade name Manufacturer Predicate number K073316 CERAMENTBONE VOID FILLER Bonesupport AB Primary predicate CERAMENTBONE VOID FILLE…
Bonesupport AB2008—
†K090871Cerament Ibone Void Filler High Contrast, Model a 0210-12Bonesupport AB2009—
†K132656Prodense Bone Graft SubstituteWrightmedicaltechnologyinc2014—
†K113871Pro-Dense Bone Graft SubstituteWrightmedicaltechnologyinc2013—
†K102722Norian Drillable Inject, Norian Drillable Fast Set PuttySynthes USA Products, LLC20114

Also cleared against K073316: 1 other device →

What descends from it? (3)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K212083Tactoset Injectable Bone SubstituteAnika Therapeutics, Inc.20212
K231968Tactoset® Injectable Bone SubstituteAnika Therapeutics, Inc.20230

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 24 years and passes through 5 companies; a new generation was cleared every 2.7 years on median.
  • None of the 14 ancestors has a recall.
  • Of its descendants, K212083 (Anika Therapeutics, Inc., 2021) has gone furthest, with 2 descendants of its own.
  • 1 other device also cites its predicate K073316.

How does its category compare?

All MQV devices

MQV Filler, Bone Void, Calcium Compound: FDA decisions, review times, recalls and adverse event reports over 20 years. 2020, this device’s year, is highlighted.

FDA decisions per year · MQV

14in 2025

2007: 352008: 322009: 232010: 172011: 162012: 92013: 122014: 202015: 182016: 82017: 172018: 232019: 132020: 152021: 82022: 92023: 212024: 282025: 142026 (partial year): 5
2007high 35 (2007) · low 8 (2016)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MQV

57in 2025

2007: 144 days median2008: 102 days median2009: 180 days median2010: 147 days median2011: 92 days median2012: 107 days median2013: 197 days median2014: 153 days median2015: 184 days median2016: 214 days median2017: 124 days median2018: 124 days median2019: 90 days median2020: 132 days median2021: 88 days median2022: 118 days median2023: 74 days median2024: 55 days median2025: 57 days median2026 (partial year): 96 days median
2007high 214 (2016) · low 55 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MQV

1in 2025

2007: 52008: 32009: 12011: 62012: 32013: 22016: 12017: 12018: 22020: 12023: 32024: 22025: 12026 (partial year): 4
2007high 6 (2011) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MQV

57in 2025

2007: 672008: 712009: 812010: 682011: 1142012: 1492013: 2232014: 1112015: 1252016: 1062017: 1072018: 862019: 652020: 1262021: 1012022: 472023: 1202024: 682025: 57
2007high 223 (2013) · low 47 (2022)2025

MAUDE reports naming product code MQV, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200735144567
200832102371
200923180181
201017147068
201116926114
201291073149
2013121972223
2014201530111
2015181840125
201682141106
2017171241107
201823124286
20191390065
2020151321126
20218880101
20229118047
202321743120
20242855268
20251457157
20265964—

What is it indicated for?

CERAMENT | BONE VOID FILLER is a ceramic bone graft substitute intended for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. CERAMENT | BONE VOID FILLER is indicated to be injected, or placed, into bony voids or gaps in the skeletal system, i.e. extremities, pelvis, and posterolateral spine (only during open surgery in spine). These defects may be the result of benign bone cysts and…

Read the full statement (171 words)

CERAMENT | BONE VOID FILLER is a ceramic bone graft substitute intended for orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.

CERAMENT | BONE VOID FILLER is indicated to be injected, or placed, into bony voids or gaps in the skeletal system, i.e. extremities, pelvis, and posterolateral spine (only during open surgery in spine). These defects may be the result of benign bone cysts and tumors (in adults and pediatric patients > 9 years old), or osseous defects created as a result of either surgery or traumatic injury to the bone.

CERAMENT | BONE VOID FILLER resorbs and is replaced by bone during the healing process.

CERAMENT | BONE VOID FILLER can augment hardware and support bone fragments during the surgical procedure.

The cured paste acts only as a temporary support media and is not intended to provide structural support during the healing process. CERAMENT | BONE VOID FILLER can be drilled and screws can be placed through it.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K201535: Cerament Bone Void Filler.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K201535

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026